Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.33 |
| ▸ | RXRA | P19793 | 7/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438652 | 0.91 | CTSS (0.39) | CCR1TP53CTSSCTSKAPLNR | |
| SCHEMBL27670848 | 0.88 | SRC (0.32) | TP53CTSSCTSKAPLNRMEN1 | |
| SCHEMBL5431917 | 0.84 | CNR1 (0.39) | TP53 | |
| SCHEMBL5429779 | 0.82 | TP53 (0.39) | CCR1TP53MEN1KMT2A | |
| SCHEMBL5432034 | 0.81 | NPSR1 (0.41) | TP53MEN1KMT2A | |
| SCHEMBL5434559 | 0.79 | MAOA (0.39) | — | |
| SCHEMBL5433744 | 0.78 | CTSS (0.38) | CTSSCTSKMEN1KMT2A | |
| SCHEMBL5426635 | 0.78 | CYP2C19 (0.43) | — | |
| SCHEMBL5431789 | 0.77 | GRM1 (0.36) | TP53MEN1KMT2ACYP11B2 | |
| SCHEMBL5431688 | 0.76 | MEN1 (0.33) | TP53CTSSAPLNRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | claimed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | CCR1 346/4885TP53 4137/4885CTSS 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.